Sugi Predict

Sugi Predict / Compounds / SCHEMBL231824

SCHEMBL231824

SCHEMBL231824

CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ NR5A2 O00482 1/20 1.00
▸ NR5A1 Q13285 1/20 1.00
▸ MAPT P10636 3/20 0.88
▸ FABP3 P05413 1/20 0.78
▸ RECQL P46063 1/20 0.77
▸ ALDH1A1 P00352 1/20 0.68
▸ ADRA1D P25100 1/20 0.66
▸ PTAFR P25105 1/20 0.66
▸ HTR1D P28221 1/20 0.66
▸ HTR2C P28335 1/20 0.66
▸ ADRA1B P35368 1/20 0.66
▸ DRD3 P35462 1/20 0.66
▸ TMEM97 Q5BJF2 1/20 0.66
▸ LPAR3 Q9UBY5 3/20 0.63
▸ LPAR1 Q92633 2/20 0.63
▸ ENPP2 Q13822 1/20 0.63
▸ MAPK1 P28482 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ GMNN O75496 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimyristoylphosphatidylcholine SCHEMBL244839 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL10498112 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Dimyristoylphosphatidylcholine SCHEMBL37475 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL234790 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL233046 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL22693933 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Dimyristoylphosphatidylcholine SCHEMBL236969 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL2036043 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL24563 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Colfosceril Palmitate SCHEMBL2734250 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028310-A1 LIPID COMPOUND AND USES THEREOF LONGUIDE BIOPHARMA CORP (CN) 2026-01-29 — — US claimed
WO-2024053974-A1 COMPOSITION FOR PHOTOTHERMAL THERAPY AND PREPARATION METHOD THEREFOR 서울대학교산학협력단 2024-03-14 — — WO claimed
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF CODIAK BIOSCIENCES, INC. (US) 2022-11-10 — — US claimed
EP-4017537-A1 SILK PERSONAL CARE COMPOSITIONS Evolved by Nature, Inc. (US) 2022-06-29 — — EP claimed
US-20260028310-A1 LIPID COMPOUND AND USES THEREOF LONGUIDE BIOPHARMA CORP (CN) 2026-01-29 — — US disclosed
EP-4646109-A2 NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS Invaio Sciences, Inc. (US) 2025-11-12 — — EP disclosed
EP-4637812-A1 HEPATITIS B COMPOSITIONS GlaxoSmithKline Biologicals S.A. (BE) 2025-10-29 — — EP disclosed
CN-119632928-A Several liposomal cannabinoids and uses thereof 耶路撒冷希伯来大学伊森姆研究发展有限公司 2025-03-18 — — CN disclosed
CN-118961905-A Craniopharyngeoma serum metabolite spectrum, intestinal flora spectrum and application thereof 复旦大学附属华山医院 2024-11-15 — — CN disclosed
WO-2024168193-A2 NATURAL LIPID PARTICLE FORMULATIONS FOR AGRICULTURAL APPLICATIONS INVAIO SCIENCES, INC. (US) 2024-08-15 — — WO disclosed
EP-4412593-A1 NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-08-14 — — EP disclosed
WO-2024133160-A1 HEPATITIS B COMPOSITIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-27 — — WO disclosed
CN-114641570-A Extracellular vesicles with KRAS-targeted antisense oligonucleotides 科迪亚克生物科学公司 2022-06-17 — — CN disclosed
CN-113966348-A Security particles with controlled activation for introducing useful chemical agents into the body 班布沃尔特有限公司 2022-01-21 — — CN disclosed
EP-2578237-A1 Compositions and methods for enhancing contrast in imaging Marval Biosciences, Inc. (US) 2013-04-10 — — EP disclosed
US-20120003159-A1 COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-05 — — US disclosed
US-7785568-B2 Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography MARVAL BIOSCIENCES, INC. (US) 2010-08-31 — — US disclosed
US-20100129430-A1 LIPOSOME DRUG CARRIERS WITH PH-SENSITIVITY POLYTECHNIC UNIVERSITY 2010-05-27 — — US disclosed
US-20080131369-A1 Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography MARVEL THERAPEUTICS (US) 2008-06-05 — — US disclosed
US-20070212303-A1 Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography MARVAL PHARMA, INC. 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF EXOSC5, EXOSC4, EXOSC10 SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885
US-20260028310-A1 LIPID COMPOUND AND USES THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, LDLR, NR1H3 SMN1; SMN2 1691/4885NR5A2 1102/4885NR5A1 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.